The call highlighted strong growth in pharmaceutical sales and robust pipeline development, particularly in oncology and neurology. However, challenges in the Diagnostics segment due to China's pricing reforms and mixed clinical trial results tempered the positive outlook. Additionally, regulatory setbacks and geopolitical uncertainties added caution.

Company Guidance -

Q4 2025

In the call, Roche provided comprehensive guidance on its financial and operational performance, highlighting several key metrics and strategic decisions. The Group reported a 7% increase in overall sales, driven by a strong 10% growth in the Pharmaceuticals division, with notable contributions from products like Phesgo and Xolair. Diagnostics, although flat overall due to China’s healthcare pricing reforms, would have grown by 6% without these reforms. Core operating profit increased by 11%, with a core operating margin up by 1.1 percentage points and core EPS growing 12%. The company updated its full-year guidance, lowering the LOE impact from CHF 1.2 billion to CHF 1 billion. Roche is also advancing its pipeline, with four medicines moving into Phase III and expectations for 8 to 11 more by year-end. Additionally, Roche is maintaining strong cost management, saving CHF 1 billion, aiming for CHF 3 billion in savings by 2030, and reallocating resources efficiently to support innovation and R&D excellence. Despite geopolitical uncertainties, Roche maintains a conservative approach to its guidance, emphasizing its track record of meeting or exceeding expectations.

Strong Overall Growth

Group sales increased by 7%, driven by a 10% growth in Pharma, with core operating profit growing by 11% and core EPS by 12%.

Pharmaceutical Achievements

EU approval of Itovebi and U.S. approval of Susvimo. Significant progress in the oncology and neurology segments, with Xolair and Ocrevus showing strong momentum.

Pipeline Development

Four new medicines moved into Phase III trials, with plans for more advancements. Positive Phase II data for fenebrutinib in MS and promising Phase II data for prasi in Parkinson's.

Diagnostics Innovation

Launch of new products including sequencing solutions and the Accu-Chek SmartGuide. Notable advancements in mass spectrometry and pathology assays.

Roche Holding AG (CH:ROG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CH:ROG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 29, 2026	2025 (Q4)	9.27 / -	8.57	―	―	―
Jul 24, 2025	2025 (Q2)	10.77 / 11.08	10.23	8.31% (+0.85)
Jan 30, 2025	2024 (Q4)	8.12 / 8.57	8.47	1.18% (+0.10)
Jul 25, 2024	2024 (Q2)	9.37 / 10.23	34.746	-70.56% (-24.52)
Feb 01, 2024	2023 (Q4)	8.37 / 8.47	8.27	2.42% (+0.20)
Jul 27, 2023	2023 (Q2)	10.15 / 34.75	11.76	195.46% (+22.99)
Feb 02, 2023	2022 (Q4)	8.64 / 8.27	9.25	-10.59% (-0.98)
Jul 21, 2022	2022 (Q2)	11.09 / 11.76	10.56	11.36% (+1.20)	―	―
Feb 03, 2022	2021 (Q4)	9.54 / 9.25	8.71	6.20% (+0.54)	―	―
Jul 22, 2021	2021 (Q2)	8.12 / 10.56	10.44	1.15% (+0.12)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CH:ROG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	CHF261.30	CHF265.10	+1.45%
Jan 30, 2025	CHF271.81	CHF276.07	+1.57%
Jul 25, 2024	CHF264.74	CHF268.62	+1.46%
Feb 01, 2024	CHF229.66	CHF217.02	-5.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Roche Holding (CH:ROG) report earnings?

Roche Holding (CH:ROG) is schdueled to report earning on Jan 29, 2026, Before Open (Confirmed).

What is Roche Holding (CH:ROG) earnings time?

Roche Holding (CH:ROG) earnings time is at Jan 29, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Roche Holding stock?

The P/E ratio of Roche Holding AG is N/A.

What is CH:ROG EPS forecast?

CH:ROG EPS forecast for the fiscal quarter 2025 (Q4) is 9.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing